Reviva Pharmaceuticals Holdingsincis A Late Stage Biopharmaceutical Company Based In Cupertinocaliforniait Focuses On Developing Innovative Therapies For Significant Unmet Medical Needsparticularly In Central Nervous Systemcardiovascularmetabolicand Inflammatory Diseasesthe Company Is Publicly Traded On The Nasdaq Under The Ticker Rvph Reviva Employs A Chemical Genomics Driven Technology Platform To Discover And Develop New Chemical Entitiesthis Approach Supports The Creation Of Novel Medicines Aimed At Improving Treatment Optionsthe Company S Pipeline Includes Two Primary Drug Candidatesbrilaroxazinerp5063 Which Is Being Developed For Schizophrenia And Has Shown Promising Results In Clinical Trialsand Rp1208Another New Chemical Entity With Undisclosed Details About Its Target Indicationreviva Is Committed To Advancing Its Pipeline And Believes In The Potential Of Its Therapies To Address Major Healthcare Challenges
